InflaRx N.V - Asset Resilience Ratio
InflaRx N.V (IF0) has an Asset Resilience Ratio of 55.12% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how InflaRx N.V's Asset Resilience Ratio has changed over time. Check InflaRx N.V strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down InflaRx N.V's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see InflaRx N.V (IF0) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.44 Million | 55.12% |
| Total Liquid Assets | €30.44 Million | 55.12% |
Asset Resilience Insights
- Very High Liquidity: InflaRx N.V maintains exceptional liquid asset reserves at 55.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
InflaRx N.V Industry Peers by Asset Resilience Ratio
Compare InflaRx N.V's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Syndax Pharmaceuticals Inc
NASDAQ:SNDX |
Biotechnology | 46.79% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 63.47% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for InflaRx N.V (2018–2025)
The table below shows the annual Asset Resilience Ratio data for InflaRx N.V.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 55.12% | €30.44 Million ≈ $35.58 Million |
€55.22 Million ≈ $64.55 Million |
+9.79pp |
| 2024-12-31 | 45.33% | €34.46 Million ≈ $40.29 Million |
€76.02 Million ≈ $88.87 Million |
-19.14pp |
| 2023-12-31 | 64.48% | €77.50 Million ≈ $90.61 Million |
€120.21 Million ≈ $140.54 Million |
+0.47pp |
| 2022-12-31 | 64.01% | €65.54 Million ≈ $76.63 Million |
€102.40 Million ≈ $119.72 Million |
+18.33pp |
| 2021-12-31 | 45.68% | €57.16 Million ≈ $66.83 Million |
€125.14 Million ≈ $146.30 Million |
-16.85pp |
| 2020-12-31 | 62.53% | €55.16 Million ≈ $64.49 Million |
€88.22 Million ≈ $103.13 Million |
-5.21pp |
| 2019-12-31 | 67.74% | €82.35 Million ≈ $96.28 Million |
€121.58 Million ≈ $142.14 Million |
+4.19pp |
| 2018-12-31 | 63.55% | €101.18 Million ≈ $118.29 Million |
€159.21 Million ≈ $186.14 Million |
-- |
About InflaRx N.V
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinic… Read more